Ivermectin
Neither the FDA nor the NIH recommend Ivermectin for the treatment of COVID 19 due to lack of empirical evidence. Per the FDA, clinical studies are currently ongoing. Thus, the FDA won’t grant approval until studies provide evidence suggesting that ivermectin treats COVID 19 efficiently.
- WHO did not find evidence to support the use of ivermectin outside of clinical studies for the treatment of COVID 19.
- Merck announced that after reviewing available data, the company has concluded there is a lack of pre-clinical, clinical and safety data to support the use of ivermectin as a treatment for COVID-19.
- In the 21-day, 400 patient, Phase III, EPIC trial (NCT04405843), a five-day course of ivermectin did not reduce the time to resolution of symptoms compared to placebo in patients with mild COVID-19.
- In the 28-day, 490 patient, Phase III, I-TECH trial (NCT04920942), treatment with ivermectin did not reduce the percentage of patients that progressed to severe COVID-19 in high-risk Malaysian outpatients with COVID-19.
- In the 28-day, 3,515 patient, Phase III, TOGETHER trial (NCT04727424), treatment with ivermectin did not reduce COVID-19 hospitalizations or urgent-care visits compared to placebo in high-risk Brazilian outpatients with COVID-19.
- The Front Line COVID-19 Critical Care Alliance, recommends the use of ivermectin for the prevention and treatment of COVID 19.
- A pre-print draft of an Indian study, found that patients treated with ivermectin did not clear the virus faster, but had a lower mortality rate (0/55) compared to patients on placebo (4/57).
- The drug was being taken to treat or prevent COVID-19.
- Most of the patients were treating themselves using a veterinary formulation. Some of the patients were taking a dose much higher than the 21 mg used in humans.
- Six of the patients were hospitalized and four admitted to the ICU.
Services |
Company |
|